Literature DB >> 32989941

Design of the Redefining Therapy in Early COPD Study.

MeiLan K Han1, Wen Ye2, Dong-Yun Kim3, Prescott Woodruff4.   

Abstract

Redefining Therapy in Early COPD (RETHINC) is a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily in symptomatic current and former smokers with respiratory symptoms as defined by COPD Assessment Test (CAT) score ≥ 10 despite preserved spirometry defined by post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio ≥ 0.70. Recruitment began in July 2017 with the goal of enrolling 580 participants. The baseline examination includes spirometry (with slow and forced maneuvers) and symptom questionnaires. A follow-up phone call at 4 weeks assesses symptoms and safety. The second and final visit at week 12 includes spirometry before and after study drug (hourly over 3 hours) and follow-up symptom questionnaires. The primary endpoint is the proportion of individuals who experience a 4-unit improvement in St George's Respiratory Questionnaire (SGRQ) score at 12 weeks without treatment failure, defined as an increase in lower respiratory symptoms necessitating treatment with active, long-acting inhaled bronchodilators, corticosteroids or antibiotics. Key secondary endpoints include the proportion of individuals with a 2-unit improvement in the CAT score; 1-unit improvement in the Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI), both a 4-unit improvement in SGRQ and a 1-unit improvement in BDI/TDI; and mean change in SGRQ, CAT and BDI/TDI. Other secondary endpoints include area under the curve 0-3 hours for FEV1 after study drug, change from baseline in trough inspiratory capacity, forced expiratory flow 25%-75% of FVC (FEF25-75) iso-volume FEF25-75 and mean change in symptoms and rescue medication use based on daily diary. We anticipate results to be available in 2021. This paper describes the RETHINC study and explains the rationale behind it. JCOPDF
© 2020.

Entities:  

Keywords:  dual bronchodilator; early COPD

Year:  2020        PMID: 32989941      PMCID: PMC7883914          DOI: 10.15326/jcopdf.7.4.2020.0157

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  12 in total

1.  Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD.

Authors:  Donald A Mahler; Joseph Ward; Gustavo Fierro-Carrion; Laurie A Waterman; Timothy F Lentine; Roberto Mejia-Alfaro; John C Baird
Journal:  COPD       Date:  2004       Impact factor: 2.409

2.  FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Donald A Mahler; Edward Kerwin; Tim Ayers; Angel FowlerTaylor; Samopriyo Maitra; Chau Thach; Mark Lloyd; Francesco Patalano; Donald Banerji
Journal:  Am J Respir Crit Care Med       Date:  2015-11-01       Impact factor: 21.405

Review 3.  The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide.

Authors:  Barbara Bp Yawn; Byron Thomashaw; David M Mannino; MeiLan K Han; Ravi Kalhan; Stephen Rennard; Scott Cerrata; James D Crapo; Robert Wise
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-15

Review 4.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

5.  Airway Mucin Concentration as a Marker of Chronic Bronchitis.

Authors:  Mehmet Kesimer; Amina A Ford; Agathe Ceppe; Giorgia Radicioni; Rui Cao; C William Davis; Claire M Doerschuk; Neil E Alexis; Wayne H Anderson; Ashley G Henderson; R Graham Barr; Eugene R Bleecker; Stephanie A Christenson; Christopher B Cooper; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Richard E Kanner; Fernando Martinez; Robert Paine; Prescott G Woodruff; Wanda K O'Neal; Richard C Boucher
Journal:  N Engl J Med       Date:  2017-09-07       Impact factor: 91.245

6.  Clinical and Radiologic Disease in Smokers With Normal Spirometry.

Authors:  Elizabeth A Regan; David A Lynch; Douglas Curran-Everett; Jeffrey L Curtis; John H M Austin; Philippe A Grenier; Hans-Ulrich Kauczor; William C Bailey; Dawn L DeMeo; Richard H Casaburi; Paul Friedman; Edwin J R Van Beek; John E Hokanson; Russell P Bowler; Terri H Beaty; George R Washko; MeiLan K Han; Victor Kim; Song Soo Kim; Kunihiro Yagihashi; Lacey Washington; Charlene E McEvoy; Clint Tanner; David M Mannino; Barry J Make; Edwin K Silverman; James D Crapo
Journal:  JAMA Intern Med       Date:  2015-09       Impact factor: 21.873

7.  Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes.

Authors:  Donald A Mahler; Laurie A Waterman; Joseph Ward; Corliss McCusker; Richard ZuWallack; John C Baird
Journal:  Chest       Date:  2007-07-23       Impact factor: 9.410

8.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

Authors:  J Vestbo; E Prescott; P Lange
Journal:  Am J Respir Crit Care Med       Date:  1996-05       Impact factor: 21.405

Review 9.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

10.  Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study.

Authors:  W C Tan; J Bourbeau; P Hernandez; K R Chapman; R Cowie; J M FitzGerald; D D Marciniuk; F Maltais; A S Buist; D E O'Donnell; D D Sin; S D Aaron
Journal:  Thorax       Date:  2014-04-04       Impact factor: 9.139

View more
  4 in total

1.  Journal Club-Respiratory Impairment With A Preserved Spirometric Ratio.

Authors:  Takudzwa Mkorombindo; Ron Balkissoon
Journal:  Chronic Obstr Pulm Dis       Date:  2022-01-27

Review 2.  Catching "Early" COPD - The Diagnostic Conundrum.

Authors:  Kay Por Yip; Robert A Stockley; Elizabeth Sapey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-04-13

3.  Association Between Non-obstructive Chronic Bronchitis and Incident Chronic Obstructive Pulmonary Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis.

Authors:  Fan Wu; Huanhuan Fan; Jing Liu; Haiqing Li; Weifeng Zeng; Silan Zheng; Heshen Tian; Zhishan Deng; Youlan Zheng; Ningning Zhao; Guoping Hu; Yumin Zhou; Pixin Ran
Journal:  Front Med (Lausanne)       Date:  2022-01-25

4.  Small airway function measured using forced expiratory flow between 25% and 75% of vital capacity and its relationship to airflow limitation in symptomatic ever-smokers: a cross-sectional study.

Authors:  Nowaf Y Alobaidi; Mohammed Almeshari; James Stockley; Robert Andrew Stockley; Elizabeth Sapey
Journal:  BMJ Open Respir Res       Date:  2022-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.